XML 48 R37.htm IDEA: XBRL DOCUMENT v3.25.3

Research and Development and In-Licensing Arrangement - Narrative (Details) - USD ($) $ in Millions	1 Months Ended			3 Months Ended		9 Months Ended
	Sep. 28, 2025	Jul. 31, 2025	Mar. 30, 2025	Sep. 28, 2025	Sep. 29, 2024	Sep. 28, 2025	Sep. 29, 2024
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Acquired in-process research and development expenses				$ 1,390	$ 13	$ 1,401	$ 20
Abingworth [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development arrangement, maximum funding amount	$ 200
Abingworth [Member] | Clinical Trial Agreement Terms [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential cash payments	$ 120			$ 120		$ 120
Abingworth [Member] | Approval Based Payment Period [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment period (in years)	18 years			18 years		18 years
Abingworth [Member] | Net Sales and Royalty Agreement Terms [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential cash payments	$ 280			$ 280		$ 280
Payment period (in years)	1 year			1 year		1 year
Blackstone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development arrangement, maximum funding amount			$ 326
Blackstone [Member] | Clinical Trial Agreement Terms [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential cash payments			277
Blackstone [Member] | Approval Based Payment Period [Member] | Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment period (in years)	1 year			1 year		1 year
Blackstone [Member] | Approval Based Payment Period [Member] | Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment period (in years)	3 years			3 years		3 years
Blackstone [Member] | Net Sales and Royalty Agreement Terms [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential cash payments			$ 897
Blackstone [Member] | Net Sales and Royalty Agreement Terms [Member] | Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment period (in years)	5 years			5 years		5 years
Blackstone [Member] | Net Sales and Royalty Agreement Terms [Member] | Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment period (in years)	7 years			7 years		7 years
3SBio [Member] | In-Licensing Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential cash payments		$ 4,800
Upfront payment		1,250
Equity investment		100
3SBio [Member] | In-Licensing Agreement Option [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment		100
Option exercise fee		50
Acquired in-process research and development expenses		$ 1,350		$ 1,350		$ 1,350

X

- Definition

Research And Development Arrangement, Contingent Payments, Maximum Exposure1

+ References

No definition available.

+ Details

Name:	pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Research And Development Arrangement, Contingent Payments, Option Exercise Fee

+ References

No definition available.

+ Details

Name:	pfe_ResearchAndDevelopmentArrangementContingentPaymentsOptionExerciseFee
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Research And Development Arrangement, Contingent Payments, Payment Period

+ References

No definition available.

+ Details

Name:	pfe_ResearchAndDevelopmentArrangementContingentPaymentsPaymentPeriod
Namespace Prefix:	pfe_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Research And Development Arrangement, Maximum Funding Amount

+ References

No definition available.

+ Details

Name:	pfe_ResearchAndDevelopmentArrangementMaximumFundingAmount
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Research And Development Arrangement, Upfront Payment

+ References

No definition available.

+ Details

Name:	pfe_ResearchAndDevelopmentArrangementUpfrontPayment
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-19

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-SubTopic 10
-Topic 321
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479567/321-10-45-1

+ Details

Name:	us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-21

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=pfe_AbingworthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfe_ClinicalTrialAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfe_ApprovalBasedPaymentPeriodMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfe_NetSalesAndRoyaltyAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=pfe_BlackstoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=pfe_A3SBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_InLicensingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_InLicensingAgreementOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: